Table 3 Clinical characteristics and cancer-specific survival in patients with inoperable gastro-oesophageal cancer receiving active treatment: multivariate survival analysis

From: Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer

 

Patients ( n =195)

Hazard ratio (95% CI)

P -value

Age (<65/65–74/>75 years)

74/49/72

1.13 (0.88–1.45)

0.354

Sex (male/female)

129/66

1.14 (0.80–1.65)

0.465

Tumour type (adenocarcinoma/squamous)

142/53

1.39 (0.89–2.17)

0.154

Tumour site (oesophagus/gastric)

114/81

1.27 (0.85–1.89)

0.249

TNM stage (I/II/III/IV)

27/20/51/97

1.66 (1.36–2.03)

<0.001

GPS (0/1/2)

78/89/28

1.75 (1.35–2.26)

<0.001

Alkaline phosphatase (U/l) (Tertiles 1/2/3)

67/64/60

0.97 (0.78–1.21)

0.788

Treatment (chemotherapy/radiotherapy/endoscopic)

102/33/60

1.48 (1.15–1.90)

0.003

  1. GPS=Glasgow Prognostic score.
Back to article page